Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
Other Sizes |
|
Edratide Acetate is a tolerogenic peptide based on the sequence of the first complementarity-determining (CDR1) region of an anti-DNA monoclonal antibody (16/6 idiotype). Preliminary studies in humans confirmed data from animal models showing that edratide downregulates pathogenic cytokines, apoptosis, and IFN-a gene expression, and upregulates immunosuppressive molecules and Tregs cells in peripheral blood.
ln Vivo |
Edratide (20-50 µg; subcutaneous injection; once weekly for 10 weeks) exhibits therapeutic effects on SLE by modulating gene expression [2]. Edratide (50 μg/mouse; subcutaneous injection; 10 times a week) can lower the apoptotic rate of SLE mice, downregulate caspase-8 and caspase-3, and upregulate Bcl-xL [3].
|
---|---|
Animal Protocol |
Animal/Disease Models: 6-7 month female mice (confirmed SLE) [2]
Doses: 20-50 µg Route of Administration: subcutaneous injection; once a week for 10 weeks Experimental Results: Up-regulation of Tnfsf4, Il5ra, Zbtb20, Nid1 RNA transcripts that downregulate Tfpi and S100a8 transcripts. Animal/Disease Models: 7-8 months old BWF1 female mice with SLE [3] Doses: 50 μg/mouse Route of Administration: Sc; 10-week Experimental Results: diminished apoptosis, downregulation of caspase-8 and caspase-3, Bcl-xL is upregulated. |
References |
[1]. Urowitz MB, et al. Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study. Lupus Sci Med. 2015 Aug 11;2(1):e000104.
[2]. Elmann A, et al. Altered gene expression in mice with lupus treated with edratide, a peptide that ameliorates the disease manifestations. Arthritis Rheum. 2007 Jul;56(7):2371-81. [3]. Sharabi A, et al. The role of apoptosis in the ameliorating effects of a CDR1-based peptide on lupus manifestations in a mouse model. J Immunol. 2007 Oct 15;179(8):4979-87. |
Molecular Formula |
C111H149N27O28
|
---|---|
Molecular Weight |
2309.53000
|
CAS # |
433922-67-9
|
SMILES |
NCCCC[C@H](NC(CNC([C@H]1N(C([C@H]2N(C(CNC(CNC=O)=O)=O)CCC2)=O)CCC1)=O)=O)C(NCC(N[C@@H](CCC(O)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC1C2=CC=CC=C2NC=1)C(N[C@@H]([C@@H](C)CC)C(NCC(O)=O)=O)=O)=O)=O)=O)=O
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~100 mg/mL (~43.30 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (1.08 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (1.08 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (1.08 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 0.4330 mL | 2.1649 mL | 4.3299 mL | |
5 mM | 0.0866 mL | 0.4330 mL | 0.8660 mL | |
10 mM | 0.0433 mL | 0.2165 mL | 0.4330 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.